Hepatitis B Infects 250 Million People. The First Drug Aimed at a Cure Just Got Approved.

Chronic hepatitis B is one of the largest untreated problems in global medicine: roughly 250 million people carry the virus, and standard antivirals — tenofovir, entecavir — suppress it well but almost never clear it, which means pills for life and a lingering risk of cirrhosis and liver cancer. On October 20, 2026, the FDA approved bepirovirsen (Hibsago) for certain adults with chronic hepatitis B without cirrhosis, in combination with existing antiviral therapy. It is the first approved drug whose explicit goal is what hepatologists call a functional cure.

What a “functional cure” is — and is not

A functional cure does not mean the virus is eradicated. Hepatitis B leaves copies of its DNA archived inside liver cells, and current drugs cannot evict them. The realistic target is narrower and still meaningful: drive the virus’s surface antigen — HBsAg, the protein whose persistence defines chronic infection — down to undetectable levels, and keep it there after treatment stops. Patients who reach that state have markedly lower rates of liver complications, even though the archive remains.

Bepirovirsen attacks the problem from two directions at once. It is an antisense oligonucleotide — a short strand of synthetic genetic material that binds the virus’s RNA and flags it for destruction, cutting off production of HBsAg and other viral proteins. It is also designed to stimulate the host immune response against infected cells. The logic: lower the antigen burden enough, and the exhausted immune system may recover control on its own.

For fifty years the best offer to a chronic hepatitis B patient was suppression forever. The question bepirovirsen asks is whether some patients can stop treatment and keep the virus down themselves.

Keep the numbers in proportion

The honest framing is that this is a first step, not a finish line. In the phase 2b B-Clear trial, the regimen produced sustained HBsAg loss in roughly one in ten treated patients — a real effect in a disease where spontaneous clearance on suppressive therapy is rare, but far from a cure for most. The approval is also narrower than the disease: it covers adults without cirrhosis, alongside existing antivirals, not as a standalone replacement for them.

Who the one-in-ten are — and whether combination with other immune-directed agents can push the rate higher — is now the central research question. Baseline antigen levels, how long someone has been infected, and the virus’s genotype all appear to matter. Expect the next wave of trials to be about stacking bepirovirsen with other mechanisms rather than using it alone.

Why it matters beyond hepatitis B

The approval is also a proof point for antisense medicine as a platform. The same chemistry — designed RNA-binding strands that silence a specific genetic message — is being aimed at Huntington’s disease, transthyretin amyloidosis, and a growing list of conditions once considered undruggable. Each approval makes the next one easier to fund, manufacture and regulate.

What a reader should take from this: if you live with chronic hepatitis B and are well controlled on antivirals, this approval does not mean stopping your current medication — the new drug is approved on top of it, for a specific group, and your hepatologist is the right person to ask whether you fit it. The larger news is directional: after decades of management, hepatitis B research is now openly organized around cure. That was not true five years ago.

This article is general information, not medical advice. See our Editorial Standards.